Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lulizumab PK Study: Prefilled Syringe vs Vial
NCT03058822Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lulizumab pegol in systemic lupus erythematosus (SLE) and Sjögren's syndrome (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Relative bioavailability of BMS-931699 at 43 days. Started Jan 2017; status: terminated.
02
Drugs
lulizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndrome
Beyond the preview
Go deeper on NCT03058822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058822.